Cost-effectiveness of antenatal fetal surveillance for medication-treated gestational diabetes.

Objective: To evaluate the relative cost-effectiveness of starting antenatal fetal surveillance at 32 vs. 36 weeks, in medication-treated gestational diabetes.

Methods: We performed a 2017-2022 retrospective cohort study of patients with medication-treated GDM who underwent BPPs.